-
Company Profile
Strongbridge Biopharma plc – Company Profile
Strongbridge Biopharma plc (Strongbridge) formerly Cortendo Plc, is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases. The company’s marketed product KEVEYIS (dichlorphenamide) is indicated for the treatment of hypokalemic, hyperkalemic, and related variants of primary periodic paralysis, a genetic neuromuscular disorder. Its KEVEYIS holds orphan drug designation in the US. Strongbridge's pipeline products include COR-003 (levoketoconazole) a cortisol synthesis inhibitor for the treatment of endogenous Cushing’s syndrome; and COR-005 a novel somatostatin analog for the treatment...
Add to Basket -
Product Insights
Neuroendocrine Tumors Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Neuroendocrine Tumors Pipeline Drugs Market Report Overview Neuroendocrine tumor begins in the hormone-producing cells of the body’s neuroendocrine system, which is made up of cells that are a cross between traditional endocrine cells (or hormone-producing cells) and nerve cells. Symptoms includes hyperglycemia, diarrhea, loss of appetite/weight loss, thickening or lump in any part of the body, jaundice, headache, anxiety, and gastric ulcer disease. The Neuroendocrine Tumors pipeline drugs market research report provides comprehensive information on the therapeutics under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – veldoreotide IR
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry veldoreotide IR Drug Details Veldoreotide (COR-005) is under development for the treatment of acromegaly....
-
Product Insights
Acromegaly Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Acromegaly is a hormonal disorder that develops when the pituitary gland produces too much growth hormone during adulthood. Symptoms include body odor, easy fatigue, headache, large feet, excessive height, swelling of the bony areas around a joint, widely spaced teeth, and sleep apnea. Treatment includes surgery, dopamine agonists, and growth hormone antagonists. The Acromegaly pipeline market research report provides comprehensive information on the therapeutics under development for Acromegaly, complete with analysis by stage of development, drug target, mechanism of action...
-
Product Insights
Somatostatin Receptor Type 4 (SSTR4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Somatostatin Receptor Type 4 (SSTR4) pipeline drugs market research report outlays comprehensive information on the Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Hormonal Disorders, Central Nervous System, Metabolic Disorders, and Oncology which include indications of Acromegaly, Diabetic Neuropathic Pain, Low Back Pain, Neuroendocrine Tumors, Osteoarthritis Pain, Pain, and Pituitary ACTH...
-
Sector Analysis
Cushing’s Syndrome – Opportunity Assessment and Forecast to 2030
GlobalData estimates that 2020 sales for Cushing’s syndrome (CS) therapies were approximately $121.4 million, with the US and Germany dominating the market. The sales are expected to grow at a CAGR of more than 10% during 2020-2030. GlobalData expects the number of diagnosed prevalent cases of Cushing’s syndrome (CS) to be 25,625 cases in 2020, increasing at a negligible Annual Growth Rate (AGR) of less than 1% across the two major markets. In 2020, the US had the highest number...
-
Product Insights
Paralysis Global Clinical Trials Review, H1, 2018
GlobalData's clinical trial report, “Paralysis Global Clinical Trials Review, H1, 2018" provides an overview of Paralysis clinical trials scenario. This report provides top line data relating to the clinical trials on Paralysis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...